Pulmonary Arterial Hypertension Global Market Report 2025

Description

Pulmonary arterial hypertension refers to a condition characterized by elevated blood pressure in the arteries of the lungs, leading to damage to the right side of the heart and the lung arteries. This long-lasting and incurable condition results in the constriction and rigidity of the walls of the pulmonary arteries. Pulmonary arterial hypertension drugs are designed to address this condition by relaxing the muscles in the blood vessel walls, increasing blood flow through the lungs, or reversing the effects of substances in the blood vessel walls that cause them to narrow.

The main types of drug classes for pulmonary arterial hypertension include endothelin receptor antagonists (ERAs), PDE-5 inhibitors, prostacyclin and prostacyclin analogs, and soluble guanylate cyclase (SGC) stimulators. Endothelin receptor antagonists (ERAs) are a targeted medication used for treating pulmonary hypertension in patients. Targeted medications aim to reduce the progression of pulmonary hypertension and potentially reverse some of the damage to the heart and lungs. These drugs can be administered through oral, intravenous/subcutaneous, and inhalational modes, and they are distributed through retail and online channels.

The pulmonary arterial hypertension market research report is one of a series of new reports from The Business Research Company that provides pulmonary arterial hypertension market statistics, including pulmonary arterial hypertension industry global market size, regional shares, competitors with a pulmonary arterial hypertension market share, detailed pulmonary arterial hypertension market segments, market trends and opportunities, and any further data you may need to thrive in the pulmonary arterial hypertension industry. This pulmonary arterial hypertension market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The pulmonary arterial hypertension market size has grown strongly in recent years. It will grow from $8.47 billion in 2024 to $9.24 billion in 2025 at a compound annual growth rate (CAGR) of 9.1%. The growth in the historic period can be attributed to increased awareness and diagnosis of pulmonary arterial hypertension (PAH), increased healthcare expenditure, growth in aging population, expansion of pulmonary arterial hypertension treatment options, rise in research and development activities in pulmonary hypertension.

The pulmonary arterial hypertension market size is expected to see strong growth in the next few years. It will grow to $12.97 billion in 2029 at a compound annual growth rate (CAGR) of 8.8%. The growth in the forecast period can be attributed to adoption of novel therapies for pulmonary arterial hypertension, increased focus on early detection and diagnosis, growing pipeline of PAH drugs and therapies, integration of precision medicine in PAH treatment, expansion of healthcare infrastructure in emerging markets. Major trends in the forecast period include advancements in medical imaging and diagnostic technologies, collaboration and partnerships for drug development, patient-centric approaches in pulmonary arterial hypertension management, increased use of combination therapy.

The growth of the pulmonary arterial hypertension market is being propelled by the increasing prevalence of pulmonary arterial hypertension (PAH) disease. The rise in PAH cases and the subsequent hospitalization of patients for treatment are expected to drive the demand for relevant drugs in the forecast period. According to the National Organization for Rare Disorders, Inc., a study suggests that new cases of PAH are estimated to occur in one to two individuals per million annually in the USA, equating to 500-1000 new cases each year, with similar incidence rates expected in Europe.

The increasing number of clinical trials for drug development is expected to drive the growth of the pulmonary arterial hypertension market in the future. Clinical trials for drug development are research studies aimed at assessing the safety, efficacy, and potential side effects of new drugs or treatments in humans. These trials specifically for pulmonary arterial hypertension can result in the creation of new and more effective treatments, improving quality of life, enhancing safety and efficacy, facilitating early access, and identifying cost-effective options. For example, in May 2023, Xtalks, a Canada-based company specializing in life science webinars and virtual events, reported that as of May 17, 2023, there were 452,604 clinical studies registered on ClinicalTrials.gov. Out of this total, 64,838 studies were actively seeking participants, marking an increase of 365,000 registered trials since 2021. Therefore, the rise in clinical trials for drug development is fueling the growth of the pulmonary arterial hypertension market.

Major companies in the pulmonary arterial hypertension market are developing advanced products like Winrevair to enhance treatment options and outcomes for patients with this serious condition. For example, in March 2024, Merck & Co. Inc., a US-based multinational pharmaceutical company, launched Winrevair for treating adults with pulmonary arterial hypertension. Winrevair is the first therapy approved by the Food and Drug Administration (FDA) that specifically targets activin signaling for pulmonary arterial hypertension (PAH). This innovative treatment functions by restoring the balance between pro- and anti-proliferative signals, which helps regulate the vascular cell proliferation associated with PAH. Consequently, it introduces a new class of therapy for this condition.

Major companies in the pulmonary arterial hypertension market are developing advanced products like OPSYNVI to offer improved treatment options that enhance patient outcomes and quality of life for individuals suffering from this serious condition. For example, in March 2024, Johnson & Johnson, a US-based multinational company focused on pharmaceuticals, biotechnology, and medical technologies, launched OPSYNVI for the chronic treatment of adults with pulmonary arterial hypertension. OPSYNVI can be used for patients with pulmonary arterial hypertension (PAH) who are either new to treatment or are already taking an endothelin receptor antagonist (ERA) or PDE5 inhibitor, or both. It is also appropriate for those on stable doses of macitentan 10 mg and tadalafil 40 mg, administered as separate tablets.

In May 2024, Gossamer Bio, a US-based biopharmaceutical company specializing in treatments for Pulmonary Arterial Hypertension (PAH), formed a partnership with Chiesi Farmaceutici S.p.A. This collaboration aims to leverage the strengths of both companies to enhance the treatment of pulmonary arterial hypertension (PAH) and accelerate the development of products for pulmonary hypertension associated with interstitial lung disease (PH-ILD). Chiesi Farmaceutici S.p.A. is an Italy-based pharmaceutical company.

Major companies operating in the pulmonary arterial hypertension market include United Therapeutics Corporation, Acceleron Pharma Inc., Actelion Pharmaceuticals US Inc., Bayer AG, Eli Lilly and Company, Gilead Sciences Inc., GlaxoSmithKline plc, Johnson & Johnson, Liquidia Technologies Inc., Lupin Pharmaceuticals Inc., Natco Pharma Ltd., Pfizer Inc., Sandoz AG, Teva Pharmaceutical Industries Ltd., Zydus Pharmaceutical USA Inc., Allegheny Health Network, Cedars-Sinai Medical Center, Cleveland Clinic, Houston Methodist Hospital, Johns Hopkins Medicine, Massachusetts General Hospital, Mayo Clinic, MedStar Heart & Vascular Institute, National Jewish Health, NewYork-Presbyterian Hospital, Ochsner Medical Center, Royal Brompton & Harefield NHS Foundation Trust, Rush University Medical Center, Stanford Health Care, Swedish Medical Center, Temple University Hospital, University of California Health.

North America was the largest region in the pulmonary arterial hypertension market in 2024. The regions covered in the pulmonary arterial hypertension market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the pulmonary arterial hypertension market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain.

The pulmonary arterial hypertension market includes revenues earned by entities by idiopathic, heritable, and drug and toxin-induced. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Pulmonary Arterial Hypertension Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on pulmonary arterial hypertension market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for pulmonary arterial hypertension ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The pulmonary arterial hypertension market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Drug Class: Endothelin Receptor Antagonists (ERAs); PDE-5 Inhibitors; Prostacyclin and Prostacyclin Analogs; SGC Stimulators
2) By Route Of Administration: Oral; Intravenous Or subcutaneous; Inhalational
3) By Distribution channel: Retail; Online
Subsegments:
1) By Endothelin Receptor Antagonists (ERAs): Bosentan; Ambrisentan; Macitentan
2) By PDE-5 Inhibitors: Sildenafil; Tadalafil
3) By Prostacyclin And Prostacyclin Analogs: Epoprostenol; Treprostinil; Iloprost
4) By SGC Stimulators: Riociguat
Companies Mentioned: United Therapeutics Corporation; Acceleron Pharma Inc.; Actelion Pharmaceuticals US Inc.; Bayer AG; Eli Lilly and Company
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Product Code: r22001

1. Executive Summary

2. Pulmonary Arterial Hypertension Market Characteristics

3. Pulmonary Arterial Hypertension Market Trends And Strategies

4. Pulmonary Arterial Hypertension Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Pulmonary Arterial Hypertension Growth Analysis And Strategic Analysis Framework

5.1. Global Pulmonary Arterial Hypertension PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Pulmonary Arterial Hypertension Market Growth Rate Analysis
5.4. Global Pulmonary Arterial Hypertension Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Pulmonary Arterial Hypertension Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Pulmonary Arterial Hypertension Total Addressable Market (TAM)

6. Pulmonary Arterial Hypertension Market Segmentation

6.1. Global Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Endothelin Receptor Antagonists (ERAs)
PDE-5 Inhibitors
Prostacyclin and Prostacyclin Analogs
SGC Stimulators
6.2. Global Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oral
Intravenous/ subcutaneous
Inhalational
6.3. Global Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Retail
Online
6.4. Global Pulmonary Arterial Hypertension Market, Sub-Segmentation Of Endothelin Receptor Antagonists (ERAs), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Bosentan
Ambrisentan
Macitentan
6.5. Global Pulmonary Arterial Hypertension Market, Sub-Segmentation Of PDE-5 Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Sildenafil
Tadalafil
6.6. Global Pulmonary Arterial Hypertension Market, Sub-Segmentation Of Prostacyclin And Prostacyclin Analogs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Epoprostenol
Treprostinil
Illoprost
6.7. Global Pulmonary Arterial Hypertension Market, Sub-Segmentation Of SGC Stimulators, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Riociguat

7. Pulmonary Arterial Hypertension Market Regional And Country Analysis

7.1. Global Pulmonary Arterial Hypertension Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Pulmonary Arterial Hypertension Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Pulmonary Arterial Hypertension Market

8.1. Asia-Pacific Pulmonary Arterial Hypertension Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Pulmonary Arterial Hypertension Market

9.1. China Pulmonary Arterial Hypertension Market Overview
9.2. China Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Pulmonary Arterial Hypertension Market

10.1. India Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Pulmonary Arterial Hypertension Market

11.1. Japan Pulmonary Arterial Hypertension Market Overview
11.2. Japan Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Pulmonary Arterial Hypertension Market

12.1. Australia Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Pulmonary Arterial Hypertension Market

13.1. Indonesia Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Pulmonary Arterial Hypertension Market

14.1. South Korea Pulmonary Arterial Hypertension Market Overview
14.2. South Korea Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Pulmonary Arterial Hypertension Market

15.1. Western Europe Pulmonary Arterial Hypertension Market Overview
15.2. Western Europe Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Pulmonary Arterial Hypertension Market

16.1. UK Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Pulmonary Arterial Hypertension Market

17.1. Germany Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Pulmonary Arterial Hypertension Market

18.1. France Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Pulmonary Arterial Hypertension Market

19.1. Italy Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Pulmonary Arterial Hypertension Market

20.1. Spain Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Pulmonary Arterial Hypertension Market

21.1. Eastern Europe Pulmonary Arterial Hypertension Market Overview
21.2. Eastern Europe Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Pulmonary Arterial Hypertension Market

22.1. Russia Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Pulmonary Arterial Hypertension Market

23.1. North America Pulmonary Arterial Hypertension Market Overview
23.2. North America Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Pulmonary Arterial Hypertension Market

24.1. USA Pulmonary Arterial Hypertension Market Overview
24.2. USA Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Pulmonary Arterial Hypertension Market

25.1. Canada Pulmonary Arterial Hypertension Market Overview
25.2. Canada Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Pulmonary Arterial Hypertension Market

26.1. South America Pulmonary Arterial Hypertension Market Overview
26.2. South America Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Pulmonary Arterial Hypertension Market

27.1. Brazil Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Pulmonary Arterial Hypertension Market

28.1. Middle East Pulmonary Arterial Hypertension Market Overview
28.2. Middle East Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Pulmonary Arterial Hypertension Market

29.1. Africa Pulmonary Arterial Hypertension Market Overview
29.2. Africa Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Pulmonary Arterial Hypertension Market, Segmentation By Route f Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Pulmonary Arterial Hypertension Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Pulmonary Arterial Hypertension Market Competitive Landscape And Company Profiles

30.1. Pulmonary Arterial Hypertension Market Competitive Landscape
30.2. Pulmonary Arterial Hypertension Market Company Profiles
- 30.2.1. Siemens AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Hitachi Ltd. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Wabtec Corporation Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. DXC Technology Company Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. L&T Technology Services Limited Overview, Products and Services, Strategy and Financial Analysis

31. Pulmonary Arterial Hypertension Market Other Major And Innovative Companies

31.1. SAP SE
31.2. Capgemini SE
31.3. Cisco Systems Inc.
31.4. Accenture plc
31.5. Atkins Global
31.6. Trimble Inc.
31.7. WSP Global Inc.
31.8. Tego Inc.
31.9. KONUX GmbH
31.10. Oxplus B. V.
31.11. Bentley Systems, Incorporated
31.12. Trapeze Group
31.13. Uptake Technologies Inc.
31.14. Huawei Technologies Co. Ltd.
31.15. Cyient Limited

32. Global Pulmonary Arterial Hypertension Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Pulmonary Arterial Hypertension Market

34. Recent Developments In The Pulmonary Arterial Hypertension Market

35. Pulmonary Arterial Hypertension Market High Potential Countries, Segments and Strategies

35.1 Pulmonary Arterial Hypertension Market In 2029 - Countries Offering Most New Opportunities
35.2 Pulmonary Arterial Hypertension Market In 2029 - Segments Offering Most New Opportunities
35.3 Pulmonary Arterial Hypertension Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer